RELB and myeloid sarcoma: Considering the fact that our research group has successfully alleviated established EAE by adoptive transfer of 1,25-(OH)2D3-induced tolerogenic DCs [173], in the future, the adoptive transfer of RelB-silenced tolerogenic DCs may be a promising strategy for the precise treatment of MS.